Alteryx price target raised to $45 from $40 at Truist

Truist raised the firm’s price target on Alteryx to $45 from $40 and keeps a Buy rating on the shares. The analyst cites the company’s “strong” Q3 earnings beat driven by execution improvements starting to take hold. Truist adds that heading into its biggest renewal quarter, the performance gives the firm incremental confidence in its ability to execute against an uncertain macro backdrop.